Inappropriate activation of the NOTCH signaling pathway, for example, by activating mutations, contributes to the pathogenesis of various human malignancies. Here, we demonstrate that aberrant expression of an essential NOTCH coactivator of the Mastermind-like (MAML) family provides an alternative mechanism to activate NOTCH signaling in human lymphoma cells. We detected high-level MAML2 expression in several B cell-derived lymphoma types, including classical Hodgkin lymphoma (cHL) cells, relative to normal B cells. Inhibition of MAML-protein activity by a dominant negative form of MAML or by small hairpin RNAs targeting MAML2 in cHL cells resulted in downregulation of the NOTCH target genes HES7 and HEY1, which we identified as overexpressed in cHL cells, and in reduced proliferation. Furthermore, a NOTCH gene-expression signature in cHL cells confirmed their cell-autonomous NOTCH activity. Finally, in line with the essential role of MAML proteins for assembly and activity of the NOTCH transcriptional complex (NTC), we show that MAMLderived small-peptide constructs block NOTCH activity and disrupt NTC formation in vitro. These data strongly suggest direct targeting of the NTC as treatment strategy for NOTCH-dependent malignancies.
Introduction
Numerous studies revealed a fundamental role of the NOTCH signaling pathway for key processes such as cellular differentiation, growth and apoptosis regulation (Koch and Radtke, 2007; Kopan and Ilagan, 2009 ).
In Mammalia there are four NOTCH receptors that interact with a still growing list of ligands (Kopan and Ilagan, 2009) . Upon ligand binding, cleavage of the NOTCH receptor produces a membrane-anchored form of NOTCH termed NOTCH transmembrane (NOTCH TM ). NOTCH TM , in turn is cleaved by the g-secretase membrane protease complex, releasing intracellular NOTCH (ICN), which then translocates to the nucleus and activates transcription.
ICN does not directly bind to DNA, but interacts with the enhancer-binding protein member CSL (CBF1, Suppressor of Hairless, LAG-1) (Kopan and Ilagan, 2009 ). In the absence of ICN, CSL binds to DNA in a sequence-dependent manner and recruits various corepressor molecules. Interaction of ICN with CSL converts CSL from a transcriptional repressor to an activator (Lubman et al., 2007) by creating a dual ICN/ CSL binding interface for transcriptional coactivators of the Mastermind-like (MAML) family (Fryer et al., 2002; Jeffries et al., 2002; Del Bianco et al., 2008) . Three MAML members exist (MAML1, MAML2 and MAML3) (Lin et al., 2002; Wu et al., 2000 Wu et al., , 2002 , all of which contain an N-terminal region of approximately 60 amino acids (AA) that binds an extended groove formed by CSL and the ankyrin-domain of ICN (Nam et al., 2006; Wilson and Kovall, 2006) . Binding of MAML proteins to the ICN-CSL complex is essential for NOTCH-mediated transcriptional activation (Fryer et al., 2002; Nam et al., 2003 Nam et al., , 2006 Maillard et al., 2004) . The mechanisms by which MAML proteins regulate the fine-tuning of NOTCH signaling remain to be elucidated. However, several lines of evidence, for example, the (11;19)(q21;p13) translocation found in mucoepidermoid carcinoma that creates a MAML2 fusion protein and activates NOTCH target genes (Tonon et al., 2003) , point to the oncogenic potential of MAML dysregulation.
Deregulated NOTCH signaling results in pathological disorders, including developmental syndromes and various malignancies (Grabher et al., 2006; Koch and Radtke, 2007) . Different mechanisms leading to aberrant NOTCH activation have been unraveled so far, including activating mutations of the NOTCH1 receptor itself Grabher et al., 2006) as well as alterations in proteins that control ICN turnover (O'Neil et al., 2007) . Such defects are found in more than 50% of childhood and adult T-cell acute lymphoblastic leukemia (T-ALLs). We and others have previously shown that aberrant NOTCH activity is involved in the pathogenesis of human B cell-derived malignancies, including multiple myeloma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma and the malignant Hodgkin-/ Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) (Kapp et al., 1999; Jundt et al., 2002 Jundt et al., , 2004 Jundt et al., , 2008 Lee et al., 2009; Rosati et al., 2009; Stanelle et al., 2010) . Given the important function of MAML coactivators for NOTCH activation (Wu et al., 2002) and for the development of distinct B cell subsets (Oyama et al., 2007; Wu et al., 2007) , we analyzed the contribution of MAML to the deregulated NOTCH activity in human B cell-derived lymphomas.
Results

NOTCH1
TM and cleaved ICN1 in human B cell-derived lymphoma cell lines We first analyzed the expression levels of NOTCH1 TM and ICN1 in various cell lines by use of antibodies recognizing these different forms of NOTCH1 ( Figure 1a ). As previously published (Jundt et al., 2002) , HRS cell lines (L428, L1236, KM-H2, L591, HDLM-2, L540 and L540Cy) showed a prominent expression of NOTCH1 TM compared with most other non-Hodgkin lymphoma cell lines (Reh, Namalwa, BL-60, BJAB and SU-DHL-4). However, although ICN1 was detectable at variable levels in the cell lines (Figure 1a) Weng et al., 2003; Jundt et al., 2002 Jundt et al., , 2008 Moellering et al., 2009) . We hypothesized that altered expression or activity of NTC components other than ICN1 might explain aberrant activation of the NOTCH signaling pathway in certain cellular contexts. We therefore decided to analyze expression and activity of NOTCH coactivators of the MAML family in the various cell lines in detail.
High-level expression of MAML2 in human B cell-derived lymphomas, in particular HRS cell lines To this end, messenger RNA (mRNA) and protein expression of the three MAML family members MAML1-3 were analyzed in various HRS and nonHodgkin lymphoma cell lines (Figure 1b and Supplementary Figure 1 ). The expression levels of MAML1 did not show significant differences between HRS and non-Hodgkin cell lines, and MAML3 mRNA was, apart from KM-H2, Reh and BJAB cell lines with more prominent expression, also similarly expressed in the various cell lines. These data were confirmed at the protein level (Figure 1b ). In contrast, MAML2 mRNA was abundant in all HRS cell lines, whereas except for Reh and BL-60 cells, it was undetectable in the other non-Hodgkin lymphoma cell lines (Figure 1b, upper panel) . MAML2 protein expression correlated with the mRNA expression data (Figure 1b, lower panel) . As only few data regarding MAML expression in human lymphoid cells were available (Lin et al., 2002; Wu et al., 2002) , we analyzed MAML mRNA and protein expression in purified CD19 þ B cells and CD3 þ T cells (Figure 1c ). Robust expression of MAML1 and MAML3 mRNA was found in all lymphoid samples (Figure 1c, upper panel) . In contrast, MAML2 was strongly expressed only in CD3 þ T cells, whereas it was hardly detectable in CD19 þ B cells, which was confirmed at protein level (Figure 1c, lower panel) . We concluded that MAML2 is expressed at an aberrantly high level in several B cell-derived lymphoma cell lines, most commonly in those of cHL origin.
Aberrant MAML2 expression in distinct primary lymphoma entities Next, we analyzed MAML2 expression in non-neoplastic lymphoid tissue and 180 B cell-derived primary human lymphoma cases by immunohistochemistry ( Figure 1d and Table 1 ). In contrast to normal tonsillar B cells, high MAML2 expression was detectable in malignant cells of various primary lymphomas, in particular, in all analyzed B lymphoblastic leukemias (8/8), 40% of mantle cell lymphoma cases (4/10), approximately half of the marginal zone lymphoma cases and in the HRS cells of half of the cHL cases (30/61). Overall, these data revealed MAML2 deregulation as a common defect in B cell-derived lymphomas. Given the robust expression of MAML2 in the HRS cell lines (Figure 1) , we investigated the function of MAML2 in these cell lines in more detail.
MAML2 drives NOTCH-mediated transcriptional activation in lymphoid-derived cells and regulates the NOTCH target genes HES7 and HEY1 in cHL cells To study the function of MAML2 in lymphoid cell lines, we first assessed the potential of MAML2 to potentiate NOTCH transcriptional activity in such cells, as previous analyses were primarily performed with other cell types (Wu et al., 2000 (Wu et al., , 2002 Lin et al., 2002) . To establish the experimental system, we cotransfected HEK293 cells with a NOTCH-dependent promoter construct, and either ICN1 or MAML2 alone or in combination ( Figure 2a ). As previously published (Wu et al., 2002) , ICN1 and MAML2 synergistically activated the reporter construct. To extend this model system to one that more closely resembled HRS cell lines, which display putative cell-autonomous constitutive NOTCH1 signaling (Jundt et al., 2008; Stanelle et al., 2010) , we used the lymphoid cell line SUP-T1 (Figure 2b ), which has constitutive NOTCH1 activation because of a (7;9)(q34;q34.3) translocation (Ellisen et al., 1991) . In combination with the inherent presence of activated NOTCH1 in these cells (Figure 1a ), ectopic expression of MAML2 augmented NOTCH-dependent reporter activity 2.3-fold, similar to the super-induction by ectopically expressed ICN1. Ectopic expression of MAML2 together with ICN1 resulted in a synergistic 5.2-fold activation of reporter activity (Figure 2b ). We concluded that overexpression of MAML2 is able to super-induce NOTCH activity even in cells where ICN1 is already present.
To investigate the contribution of MAML2 to NOTCH activity in HRS cells, we first screened microarray data from various cell lines for known NOTCH target genes differentially expressed in HRS cell lines. We identified the strongly NOTCH-dependent genes HES7 and HEY1 (Iso et al., 2003) as specifically overexpressed in HRS compared with non-Hodgkin lymphoma cell lines, a finding that was confirmed by reverse transcription PCR (Figure 2c ). HES7 was NOTCH activation by high MAML2 expression K Köchert et al expressed exclusively in HRS cell lines, and HEY1 was strongly overexpressed. To evaluate the contribution of MAML2 to the activation of these genes, we tested the effect of MAML2 knockdown. Initial attempts to do so by transfection of Dharmacon (Lafayette, CO, USA) ON-TARGETplus SMARTpool MAML2 small interfering RNA were confounded by weak MAML2 knockdown (data not shown). To overcome this limitation, three of the sequences from the MAML2 small interfering RNA SMARTpool were cloned into the pSUPER expression vector (Brummelkamp et al., 2002) , which results in the efficient production of small hairpin RNA (shRNA) transcripts. Almost complete knockdown of MAML2 was achieved using this approach ( Figure 2d ). Significant downregulation of HES7 and HEY1 following MAML2 downregulation occurred in both HRS cell lines L428 and L591, suggesting that their expression was dependent on MAML2-mediated NOTCH activation ( Figure 2e ).
MAML2-mediated NOTCH activity is essential for HRS cell growth
Among other functions, NOTCH signaling regulates proliferation in various cell types. To test the role of cellautonomous NOTCH signaling for the growth of HRS cell lines, we transfected L428 and L591 cells with a wellcharacterized green fluorescent protein (GFP)-fused dominant-negative form of MAML1 described before (DnMAML1-pEGFP; Weng et al., 2003; Figure 3a) . DnMAML1-pEGFP inhibits NOTCH signaling by competing MAML coactivators off of the composite binding site formed upon ICN binding to CSL Nam et al., 2006) . Among the different MAML proteins, the residues interacting with the ankyrin domain of NOTCH and with CSL are highly conserved (Nam et al., 2006) . Furthermore, dominantnegative mutants of MAML1, MAML2 or MAML3 can inhibit NOTCH activity (Maillard et al., 2004) , and, even though with different affinity for the different NOTCH members, all three MAML members can interact with all NOTCH members (Lin et al., 2002; Wu et al., 2002) . Therefore, DnMAML1 will prevent binding of other MAML members including MAML2 into the NTC. To rule out possible general toxic effects of DnMAML1, we also investigated the B cell-derived BJAB cell line. We observed a significant DnMAML1-dependent growth inhibition of both HRS cell lines, whereas BJAB cells were unaffected (Figure 3a) . Similarly, specific knockdown of MAML2 resulted in reduced [
3 H]-thymidine incorporation in both HRS cell lines but not BJAB cells (Figure 3b) . We concluded that cell-autonomous NOTCH signaling and aberrant MAML2 expression contribute to the proliferation of HRS cell lines.
A NOTCH signature discriminates HRS from non-Hodgkin cell lines To further substantiate a HRS-specific NOTCH activity, we hypothesized that there might be a NOTCHdependent gene expression signature that separates HRS from non-Hodgkin cell lines. Based on an extensive literature screen, the BioGRID (http://www.thebiogrid. org/) and KEGG PATHWAY (http://www.genome.jp/ kegg/pathway.html) databases, and inclusion of all probe sets present on the Affymetrix Human Genome U133 Plus 2.0 array that Affymetrix NetAffx (Affymetrix, Santa Clara, CA, USA) classified under the gene ontology term 'NOTCH-signaling pathway', we created a gene set containing 102 genes associated with NOTCH signaling (see Supplementary Table 1) . Intriguingly, using this set, principal component analysis based on the microarray data resulted in a clear separation of HRS from non-Hodgkin samples (Figure 3c ). Fisher's Exact test (Po10
À11
) and GSEA (normalized enrichment score ¼ 1.34, FDR q-value ¼ 0.016) confirmed significant deregulation of our NOTCH gene set. Furthermore, NOTCH1, NOTCH2, NOTCH3 and NOTCH4 expression levels were Figure 2A) and at the protein level by western blotting (Figure 1a and Supplementary  Figures 2B-2D) , and expression levels of the NOTCH ligands delta-like 1, delta-like 3, delta-like 4, jagged 1 and jagged 2 were analyzed by quantitative real-time PCR (Supplementary Figures 3A and 3B ). These analyses demonstrated high-level NOTCH2 (in accordance with Kapp et al., 1999; Jundt et al., 2002) and JAG2 expression as a common feature of HRS cell lines in comparison with non-Hodgkin cell lines. These data suggested that at least NOTCH2 and JAG2 contribute to the cell-autonomous NOTCH activation in HRS cell lines. The HRS cell lines L428 and L591 were transfected with either control shRNA (shControl) or shMAML2 constructs (shMAML2). After enrichment of transfected cells, MAML2 protein expression was analyzed by WB. b-actin was analyzed as a control. (e) HES7 and HEY1 mRNA expression depend on MAML2. L428 and L591 HRS cell lines were transfected as described in (d). Following purification of transfected cells, expression of HES7 and HEY1 mRNA was assessed by real-time PCR and calculated using the 2 ÀDDCt method. Error bars denote 95% confidence intervals. One out of three experiments is shown. *Po0.05; **Po0.001. s.d., standard deviation.
NOTCH activation by high MAML2 expression K Köchert et al
Short peptide constructs based on AAs 13-74 of MAML1 inhibit NOTCH-mediated transcriptional activation Our data suggested that disruption of the NTC by inhibition of MAML coactivators might be a promising strategy to block aberrant NOTCH activity. The principle of such a strategy has been shown by use of DnMAML1 consisting of AAs 13-74 of MAML1 Nam et al., 2006) . We reasoned that even shorter peptides containing AA residues most important in stable assembly of the NTC could be used as basis for the development of inhibitory peptides. The energetic characteristics of the NTC have been extensively studied (Nam et al., 2006; Wilson and Kovall, 2006; Del Bianco et al., 2008) . These studies revealed that for NTC assembly the energetically most important AA residues of MAML1 are R22, R25, R26, C30, R31 and H34. On the basis of this knowledge, we constructed two peptide-GFP fusion constructs. Variant 1 encompasses the MAML1 AA 13-50 and variant 2 AA 19-35 (Figure 4a ). These constructs were tested in reporter assays in the T-ALL cell line SUP-T1 (Figure 4b ). Although inhibition of NOTCH-dependent reporter activity was not as pronounced as with the established DnMAML1 construct, DnMAML1 AA 13-50 diminished reporter activity up to 77% and DnMAML1 AA 19-35 achieved a reduction of up to 45% (Figure 4b) .
To further substantiate these findings, we assessed the ability of the DnMAML1 constructs to disturb formation of the native NTC. We performed electrophoretic mobility shift assays of nuclear extracts from HEK293 cells transfected with different combinations of NTC components and the DnMAML1 constructs. Confirming (Wu et al., 2000) , ectopic expression of MAML1, ICN1 and CSL suffices for stable formation of the NTC (Figure 4c These results were in agreement with a recently published study (Moellering et al., 2009) . We addressed these questions in human B cell-derived lymphomas and revealed an aberrant expression of MAML2 in several entities, suggesting that MAML2 deregulation and subsequent NOTCH activation is a common pathogenetic principle in these lymphomas.
Furthermore, our data demonstrate the importance of MAML2 for NOTCH target gene regulation and growth of lymphoma cells. Interestingly, no similar differences of MAML1 and MAML3 expression in the various cell types were observed, supporting the interpretation that the various MAML proteins differ in their potential to fine-tune NOTCH signaling (Lin et al., 2002) . The particular importance of MAML2 for activation of the NTC is also supported by published data, which demonstrate that MAML2 is more effective regarding the amplification of NOTCH signaling than MAML1 or MAML3 (Lin et al., 2002; Wu et al., 2002) . Furthermore, the involvement of MAML coactivators in the regulation of signaling pathways other than NOTCH (McElhinny et al., 2008) , including in the several lymphoma types deregulated NF-kB pathway (Jin et al., 2010) , has to be elucidated in future studies.
With respect to cHL, we show that the NOTCH target genes HEY1 and HES7 are specifically upregulated in HRS cell lines. Furthermore, these cell lines respond to disruption of the NTC by DnMAML1 or specific MAML2 knockdown, and a NOTCH-associated gene expression signature is sufficient to separate HRS from non-Hodgkin cell lines. These data indicate that NOTCH signaling is, in addition to its induction by ligands in situ in the lymph node (Jundt et al., 2002) , activated in HRS cells in a cell-autonomous manner.
In support of such a cell-autonomous NOTCH activation, we detected high-level JAG2 and, in accordance with published data (Kapp et al., 1999; Jundt et al., 2002) , NOTCH2 expression in HRS cell lines, providing further components of the NTC, which in turn will be accessible for activation by MAML2, as suggested by our data. NOTCH activation by high MAML2 expression K Köchert et al
Apart from indicating ongoing NOTCH signaling, HEY1 and HES7 might contribute to lymphoma pathogenesis. Both genes encode for basic helix-loophelix factors able to repress transcription and to modify cellular differentiation (Iso et al., 2003) . Furthermore, HES7 represses transcription from E-box-containing promoters by suppression of E2A/E47-activity (Bessho et al., 2001) . Interestingly, inhibition of the basic helixloop-helix transcription factor E2A has an important role for NOTCH-mediated malignant transformation (Nie et al., 2003; Li et al., 2008) and E2A inhibition contributes to the pathogenesis of various human lymphomas (Murre, 2005; Mathas et al., 2006; Lietz et al., 2007) .
Consistent with the essential function of MAML proteins for NOTCH transcriptional activity (Wu et al., 2002; Nam et al., 2003) , a truncated form of MAML1 retaining the N-terminal ICN/CSL interaction domain but lacking the C-terminal transactivation domain blocks ICN function . Based on structural and mutational analyses of the NTC (Nam et al., 2006; Del Bianco et al., 2008) , we followed up this experimental approach and designed much shorter truncated MAML variants that still blocked NTC activity, most likely by preventing binding of full-length MAML proteins into the groove formed by CSL and NOTCH. In fact, (Moellering et al., 2009) showed that the DnMAML1 AA 19-35 construct we used comprises the core a-helical AA motif that suffices for construction of a potent competitor. Using the MAML1 AAs 21-36 as template sequence, they developed stapled a-helical peptides, which effectively induced apoptosis of human NOTCH-dependent T-ALL cell lines in vitro and in vivo. Thus, the design of such small peptide inhibitors is a promising therapeutic approach to functionally disrupt the NTC. Such an approach would also be suitable for malignancies that depend on NOTCH activity but are resistant to g-secretase inhibition, a major obstacle in the clinical use of g-secretase inhibitors.
In summary, aberrant activation of MAML family coactivators represents an as yet unknown alternative mechanism of NOTCH activation. These data strongly suggest that the development of new treatment approaches interfering with NOTCH signaling should explore, more than at present, direct targeting of the NTC itself.
Materials and methods
Cell lines, culture conditions and transfections HRS (L428, L1236, KM-H2, L591 (EBV þ ), HDLM-2, L540 and L540Cy), pro-B lymphoblastic leukemia (Reh), Burkitt's lymphoma (Namalwa, BL-60 and BJAB), diffuse large B-cell lymphoma (DLBCL; SU-DHL-4), T lymphoblastic lymphoma (SUP-T1) and HEK293 cells were cultured as described . Primary CD19 þ B cells and CD3 þ T cells were isolated from human tonsils with CD19 or CD3 MicroBeads (#130-050-301 or #130-050-101; both Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's recommendation. Purity of CD19 þ B and CD3 þ T cells was greater than 95%, as determined by staining of purified cells with CD19-and CD3-specific antibodies (#R0808 and #R0810, Dako, Hamburg, Germany) and subsequent fluorescent-activated cell sorter (FACS) analysis using a FACSCantoII flow cytometer and CantoDiva software (Becton Dickinson, Heidelberg, Germany) . The use of human material was approved by the local ethics committee of the Charite´, and performed in accordance with the Declaration of Helsinki. Cells were electroporated in OPTI-MEM I using a Gene-Pulser II (Bio-Rad, Munich, Germany) with 950 mF and 0.18 kV (L428, HEK293), 500 mF and 0.3 kV (L591), 500 mF and 0.28 kV (SUP-T1), 50 mF and 0.5 kV (BJAB). Transfection efficiency was determined by pEGFP (Clontech Laboratories, Mountain View, CA, USA) cotransfection and FACS analysis or by FACS analysis of pEGFPfusion constructs, where indicated. Cells were transfected with 60 mg DnMAML1-pEGFP AA 13-74 fusion construct or 60 mg of pEGFP control plasmid, or with each 20 mg of three different shMAML2-pSuper-based expression constructs or 60 mg of scrambled shRNA construct as control, both along with 10 mg of pEGFP. At 48 h after transfection, GFP þ cells were enriched by FACS sorting and enriched cells were used for proliferation assays as well as RNA and protein preparation.
Reporter assays
For measurement of luciferase activity, HEK293 and SUP-T1 cells were transfected with 10 mg of the Hes1-pGL2 promotor construct and 100 ng pRL-TKLuc as an internal control. Where indicated, cells were cotransfected with 5 mg Flagtagged ICN1, 30 mg (HEK293) or 60 mg (SUP-T1) MAML2 expression constructs or both. Equal DNA loads were achieved by adding according amounts of empty plasmid. For assaying the functional activity of MAML1-based peptide-pEGFP constructs, SUP-T1 cells were cotransfected with 80 mg of either pEGFP, or the various DnMAML1-pEGFP constructs, as indicated, along with 10 mg of the Hes1-pGL2 promotor construct and 100 ng pRL-TKLuc as an internal control. At 48 h after transfection, cells were lysed and the ratio of the two luciferases was determined (Dual luciferase kit; Promega, Mannheim, Germany).
Plasmids and DNA constructs MAML1, MAML3 and MYC-CSL constructs were described before (Wu et al., 2000 (Wu et al., , 2002 . MAML2 was mobilized from the previously described MAML2-pEFBOS construct (Lin et al., 2002) by digestion with NotI and XhoI and cloned into pcDNA3.1( þ ) (Invitrogen, Karlsruhe, Germany). The DnMAML1-pEGFP AAs 13-74 and the ICN1-pcDNA3.1-expression constructs as well as the Hes1-pGL2 reporter construct were described previously . The truncated versions DnMAML1 AA 13-50 and AA 19-35 were cloned into pEGFP through HindIII and KpnI restriction sites using high-performance liquid chromatography grade oligonucleotides (Biotez GmbH, Berlin, Germany). Sequences for the shMAML2 constructs were selected on the basis of small interfering RNA sequences from the Dharmacon MAML2 ON-TARGETplus SMARTpool (#L-013568-00, Dharmacon). To generate shRNA expression constructs, target sequences 5 0 -GGACAAAGTCAGATTATGT-3 0 , 5 0 -CGAAA GTAATGGCTAACTA-3 0 , 5 0 -AGACCAAATTTAACCCAT A-3 0 were cloned through BglII and HindIII restriction sites into pSUPER using high-performance liquid chromatography grade oligonucleotides (Biotez GmbH). The scrambled shRNA construct has been previously described . All constructs were verified by sequencing.
RNA preparation, semi-quantitative and real-time PCR analyses RNA preparation and complementary DNA synthesis were performed as described . Primer sequences are listed in Supplementary Table 2 . Real-time PCR analyses were performed using Power SYBR Green Mastermix and the ABI StepOnePlus real-time PCR system (Applied Biosystems, Darmstadt, Germany). Relative quantities were calculated using the 2 ÀDDCt method. All PCR products were verified by sequencing.
Preparation of whole-cell and nuclear extracts and western blotting Whole-cell and nuclear-extract preparation, and western blotting were performed as described . For western blotting analyses, 30 mg of whole cell or nuclear extracts were used. Primary antibodies were: anti-MAML1 and anti-MAML2 (#4608 and #4618, Cell Signaling, Boston, MA, USA), anti-MAML3 (NB100-2129, Novus Biologicals, Cambridge, UK), anti-cleaved NOTCH1 (#2421; Cell Signaling), anti-NOTCH1 (clone mN1A; #N6786), anti-b-actin (#A5441) and anti-FLAG (#F3165; all from Sigma-Aldrich, Taufkirchen, Germany), anti-NOTCH2 (C651.6DbHN; developed by S Artanavis-Tsanakonas, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA), anti-NOTCH3 and anti-NOTCH4 (#34465 and #2423, Cell Signaling), anti-PARP1 (#sc-8007; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GFP (#BA-0702; Vector Laboratories, Burlingame, CA, USA), anti-myc (#46-0603; Invitrogen). Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies.
Proliferation assays
Proliferation of cells was determined by measurement of DNA synthesis following [ 3 H]-thymidine incorporation assays using standard protocols. Proliferation assays were measured 72 h and 96 h after transfection of cells.
Immunohistochemistry
All cases were drawn from the files of the Consultation and Reference Center for Haematopathology at the Institute of Pathology, Campus Benjamin Franklin, Medical University Berlin, Germany. Diagnoses were established according to the world health organization criteria. The primary antibody used was anti-MAML2 (#4618, Cell Signaling). Bound antibodies were made visible using the streptavidin-biotin-alkaline phosphatase method and FastRed as chromogen (all from DakoCytomation, Glostrup, Denmark).
Electrophoretic mobility shift assay CSL electrophoretic mobility shift assay was performed as described previously (Fryer et al., 2002) using the high-affinity CSL-binding site from the HES1 promoter (5 0 -CTAGGTTAC TGTGGGAAAGAAAGTCC-3 0 ). As for the shift buffer, 8%
Ficoll was used instead of glycerol. Electrophoretic mobility shift assays were performed with nuclear extracts. For preparation of nuclear extracts, HEK293 were transfected with different combinations of 10 mg Myc-tagged CSL, 10 mg Flag-tagged ICN1, 20 mg MAML1, 40 mg DnMAML1-pEGFP AA 13-74, 40 mg DnMAML1-pEGFP AA 13-50, 70 mg of DnMAML1-pEGFP AA 19-35 and total DNA amount was adjusted with empty plasmid. Cells were harvested after 48 h.
Statistical analyses of experimental and microarray data All statistical analyses were done in R v2.9.1 (http://www. r-project.org/). Independent Student's t-test was used to analyze data from proliferation-or real-time PCR-experiments. For analyses of luciferase assays, one-way analysis of variance was done before applying Tukey's Honestly Significant Differences test with 95% family-wise confidence level. For microarray analysis of the various cell lines, RNA processing and hybridization to Human Genome U133 Plus 2.0 arrays (Affymetrix) were performed according to the manufacturer's recommendation. Raw microarray data was processed using Bioconductor v2.4. RMA background correction and quantile normalization were applied. The LIMMA (Linear Models for Microarray Data) framework was used for determination of significantly differentially-expressed genes and Fisher's Exact test for testing significance of deregulation of the NOTCH gene set. Unrotated principal component analysis was applied for analysis of intensity values of NOTCH-associated genes. Gene set enrichment analysis (GSEA) was done as described in (Subramanian et al., 2005) . Microarray data are available through Gene Expression Omnibus accession number GSE20011.
